FDA premarket approvals dropped 51% in 2016 — but 2017 shaping up differently: 5 key notes

Last year there were fewer FDA approvals and it took longer for medical devices to achieve approved status; however with President Donald Trump’s vows to eliminate wasteful regulations that could change in 2017, according to Seeking Alpha.

Advertisement

Here are five things to know:

 

1. The FDA granted 38 premarket approvals to innovative devices, down 51 percent from 2015. The agency took 18.1 months to announce approval, compared with 17.3 months in 2015.

 

2. The 21st Century Cures Act went into effect in 2016, relaxing the approval criteria for medical devices, which could contribute to faster decisions and more approvals in the future.

 

3. Innovation slowdown could be another reason for fewer approvals as the large companies are finding fewer innovative technologies to acquire.

 

4. There were six humanitarian device exemptions in 2015 but none in 2016. The 21st Century Cures Act expands the number of patients HDE-approved devices can treat from 4,000 to 8,000 patients per year and speeds up the review process.

 

5. Cardiology had the most products approved last year and the fastest approval was Medtronic’s Minimed 670G system, which took 3.4 months to receive approval. On average it took orthopedic devices 37.8 months to receive approval.

 

More articles on medical devices:
Stryker shares update—7 notes
J&J, DePuy Synthes, Stryker & more: 15 device company key notes
Aurora Spine appoints Sarina Mason CFO

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.